October 30th 2024
Providers advised to halt use, monitor patients, and report any complications with BioZorb devices to the FDA.
October 30th 2024
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
First-in-Human Trial Shows Potential for CAR T-Cell Therapy in TNBC
December 18th 2018The first in-human study of CAR T cells targeting the tyrosine kinase receptor ROR1 in patients with solid tumors showed that the cells could be transferred into patients safely and expanded in vivo, according to findings from the ongoing phase I study presented at the 2018 San Antonio Breast Cancer Symposium.
Read More
Similar Late AEs Observed With Different Radiation Doses in Breast Cancer
December 14th 2018Women who received 5 fractions of 28.5 Gy over 5 weeks experienced similar adverse events as women who received 50.0 Gy in 25 fractions over 5 weeks, according to findings presented by A. Murray Brunt, MB, BS.
Read More
Conventional Views May Not Apply to All Triple-Negative Breast Cancers
December 12th 2018Clinicians need to consider the inherent heterogeneity of each case of triple-negative breast cancer during diagnosis and treatment planning, said Stuart J. Schnitt, MD, because not all cases present the same way. During the 2018 Lynn Sage Breast Cancer Symposium, Schnitt reviewed the conventional views of TNBC and emphasized that they may not fit all cases of TNBC.
Read More
Lower-Dose Tamoxifen Effective in Preventing Breast Cancer Recurrence
December 8th 2018Based on data from the phase III TAM-01 trial presented at the 41st Annual San Antonio Breast Cancer Symposium, investigators concluded that giving women diagnosed with breast intraepithelial neoplasia a lower dose of tamoxifen following surgery could be as effective and less toxic than the current standard dose.
Read More
Impact of Pertuzumab in HER2-Positive Breast Cancer
December 8th 2018Charles E. Geyer, Jr, MD, professor of medicine at Virginia Commonwealth University School of Medicine, associate director for clinical research and Harrigan, Haw, Luck Families Chair in Cancer Research at Massey Cancer Center, discusses the impact of pertuzumab (Perjeta) in the treatment of patients with HER2-positive breast cancer at the 2018 San Antonio Breast Cancer Symposium.
Watch
CTC Counts Hold Value in Therapy Selection for Metastatic Breast Cancer
December 7th 2018At the 2018 San Antonio Breast Cancer Symposium, data demonstrated that use of circulating tumor-cell counts had strong value for selecting endocrine therapy compared to chemotherapy in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.
Read More
Response to Abemaciclib in the neoMONARCH Trial
December 7th 2018Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses response to abemaciclib (Verzenio) in the neoMONARCH trial at the 2018 San Antonio Breast Cancer Symposium.
Watch
PD-L1 Immune Cell Expression Identified as Predictor of Atezolizumab Benefit in TNBC
December 7th 2018A biomarker subgroup analysis of the phase III IMpassion130 study in patients with metastatic triple negative breast cancer or inoperable locally advanced TNBC found that progression-free survival and overall survival improvements with the addition of first-line atezolizumab to nab-paclitaxel were exclusive to patients with PD-L1 expression ≥1% in immune cells.
Read More
Delaying Adjuvant Chemotherapy Linked to Worse Outcomes in TNBC
December 7th 2018Patients with triple-negative breast cancer who received chemotherapy treatment more than 30 days after surgery had worse survival rates and outcomes than patients who received adjuvant chemotherapy within 30 days of surgery, according to findings from a retrospective study presented at the 2018 San Antonio Breast Cancer Symposium.
Read More
Identification of Patients With Luminal Androgen Receptor TNBC
December 6th 2018Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses the identification of patients with luminal androgen receptor (LAR) triple-negative breast cancer (TNBC) during the 2018 San Antonio Breast Cancer Symposium.
Watch
Adjuvant Capecitabine Fails to Provide Survival Benefit in Early-Stage TNBC
December 6th 2018Adding adjuvant capecitabine to the standard treatment for patients with early-stage triple-negative breast cancer did not lead to a significant improvement in disease-free or overall survival compared with observation, according to findings presented during the 2018 San Antonio Breast Cancer Symposium
Read More
Achieving pCR After Neoadjuvant Chemo Linked to Improved Outcomes in Breast Cancer
December 6th 2018Patients with breast cancer who achieved pathologic complete response following neoadjuvant chemotherapy were more likely to have improved survival outcomes, according to findings of a meta-analyses data presented at the 2018 San Antonio Breast Cancer Symposium.
Read More
KATHERINE Findings Support T-DM1 as New Adjuvant Standard in High-Risk HER2+ Breast Cancer
December 6th 2018Findings from the phase III KATHERINE study showed adjuvant treatment with ado-trastuzumab emtansine (T-DM1; Kadcyla) reduced the risk of invasive disease recurrence or death by 50% compared with trastuzumab (Herceptin) in patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy.
Read More
Trial Investigators Discuss FDA Draft Guidance on Master Protocols
December 1st 2018Complex drug trials that use a single protocol to test either 1 agent against multiple cancers or multiple agents against 1 cancer can make drug testing faster, cheaper, and more informative, particularly when those trials use the data to constantly improve protocols.
Read More
Atezolizumab Receives Priority Review Designation From FDA for Frontline Treatment of TNBC
November 13th 2018A supplemental biologics license application for the frontline combination of atezolizumab plus nab-paclitaxel has been granted a priority review by the FDA for the treatment of patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer, based on data from the phase III IMpassion130 trial.
Read More